Mineralocorticoid Receptor Antagonist

3 · 20 / page

Ask MedXY AI

Latest news

Tag

Cardiologycardio-kidney-metabolic syndromechết đột ngột

Finerenone May Lower Sudden Death Risk Across the Cardio-Kidney-Metabolic Continuum

By MedXY|Jun 9, 2026

A prespecified pooled analysis of 18,991 participants found finerenone was associated with a significant reduction in sudden death across chronic kidney disease, type 2 diabetes, and heart failure populations.

Cardiologyclinical trialfinerenone

Mineralocorticoid Receptor Antagonist

Latest news

Finerenone May Lower Sudden Death Risk Across the Cardio-Kidney-Metabolic Continuum

Finerenone in the Management of HFmrEF and HFpEF: A Comprehensive Synthesis of Evidence from the FINEARTS-HF Trial

Diuretic-Sparing Potential of Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from FINEARTS-HF